Sarcoma News

CHICAGO — The randomized phase 3 ANNOUNCE trial failed to confirm the OS benefit of adding olaratumab to standard doxorubicin for patients with advanced soft tissue sarcoma, according to results presented during the plenary session at ASCO Annual Meeting.

CHICAGO — Pembrolizumab exhibited an acceptable safety profile among patients with cancer and HIV who had more than 100 CD4 cells/µL and received antiretroviral therapy, according to results of a phase 1 trial presented at ASCO Annual Meeting.

CHICAGO — When treating patients with serious illnesses or at the end of life, the goal of clinicians should to be help draw out and then enact patients’ goals related to their well-being, satisfaction and affordability of treatment, Atul Gawande, MD, MPH, said during the opening ceremony of ASCO Annual Meeting.

CHICAGO — The addition of temozolomide to vincristine and irinotecan may improve outcomes among children and adults with relapsed or refractory rhabdomyosarcoma, according to results of a randomized phase 2 study presented at ASCO Annual Meeting.

The California Institute for Regenerative Medicine has awarded a $4.6 million grant for a phase 1 clinical trial of a new modified blood-forming stem cell immunotherapy targeting sarcomas and other tumors that produce the NY-ESO-1 protein.

Survivors of allogeneic hematopoietic cell transplantation who underwent high-dose total body irradiation incurred nearly eight times the risk for subsequent malignant neoplasms compared with the general population, according to study results published in Blood.

Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers, according to results of a prospective study published in JAMA Network Open.

Genetic sequencing of tumors among children with refractory cancer led to about a quarter of those tested being matched with therapies targeting their specific genetic alteration, according to results of a study scheduled for presentation at ASCO Annual Meeting.

SAN FRANCISCO — Among patients with chemotherapy-induced cardiomyopathy eligible for cardiac resynchronization therapy, CRT improved left ventricular function and promoted reverse remodeling, according to the MADIT-CHIC study.

Children with central nervous system or other solid tumors with specific gene fusions responded to treatment with the investigational tyrosine kinase inhibitor entrectinib, according to results of a phase 1/1b trial scheduled for presentation at ASCO Annual Meeting.